APA

Hussein A. M., Petros W. P., Ross M., Vredenburgh J. J., Affrontil M. L., Jones R. B., Shpall E. J., Rubin P., Elkordy M., Gilbert C., Gupton C., Egorin M. J., Soper J., Berchuck A., Clarke-Person D., Berry D. A. & Peters W. P. (19960606). A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. : Cancer chemotherapy and pharmacology.

Chicago

Hussein A M, Petros W P, Ross M, Vredenburgh J J, Affrontil M L, Jones R B, Shpall E J, Rubin P, Elkordy M, Gilbert C, Gupton C, Egorin M J, Soper J, Berchuck A, Clarke-Person D, Berry D A and Peters W P. 19960606. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. : Cancer chemotherapy and pharmacology.

Harvard

Hussein A. M., Petros W. P., Ross M., Vredenburgh J. J., Affrontil M. L., Jones R. B., Shpall E. J., Rubin P., Elkordy M., Gilbert C., Gupton C., Egorin M. J., Soper J., Berchuck A., Clarke-Person D., Berry D. A. and Peters W. P. (19960606). A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. : Cancer chemotherapy and pharmacology.

MLA

Hussein A M, Petros W P, Ross M, Vredenburgh J J, Affrontil M L, Jones R B, Shpall E J, Rubin P, Elkordy M, Gilbert C, Gupton C, Egorin M J, Soper J, Berchuck A, Clarke-Person D, Berry D A and Peters W P. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. : Cancer chemotherapy and pharmacology. 19960606.